CN103102389A - 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 - Google Patents
作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 Download PDFInfo
- Publication number
- CN103102389A CN103102389A CN2012103533032A CN201210353303A CN103102389A CN 103102389 A CN103102389 A CN 103102389A CN 2012103533032 A CN2012103533032 A CN 2012103533032A CN 201210353303 A CN201210353303 A CN 201210353303A CN 103102389 A CN103102389 A CN 103102389A
- Authority
- CN
- China
- Prior art keywords
- solution
- make
- add
- mixture
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)[C@@](CC1)[C@@](C(OC)=O)N1C([C@@](*)C(C)(C)C)=O Chemical compound CC(C)[C@@](CC1)[C@@](C(OC)=O)N1C([C@@](*)C(C)(C)C)=O 0.000 description 18
- UOGOTIPFHKWQCY-VQXHTEKXSA-N CC(C)(C(C1)C2)C1[C@@H](C(C)=O)N2C(C)=O Chemical compound CC(C)(C(C1)C2)C1[C@@H](C(C)=O)N2C(C)=O UOGOTIPFHKWQCY-VQXHTEKXSA-N 0.000 description 1
- KCDNFVJMBIUAFE-UHFFFAOYSA-N CC(C)(C)OC(NC(CC1CCC1)C(C(N)=O)O)=O Chemical compound CC(C)(C)OC(NC(CC1CCC1)C(C(N)=O)O)=O KCDNFVJMBIUAFE-UHFFFAOYSA-N 0.000 description 1
- RZAUVOJLGGZGOF-MNOVXSKESA-N CC(C)(C)O[C@H](C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C)(C)O[C@H](C[C@H]1C(C)=O)CN1C(C)=O RZAUVOJLGGZGOF-MNOVXSKESA-N 0.000 description 1
- RYKHPGZFNMXWDW-UHFFFAOYSA-N CC(C)(C)SCC1(CCC1)N Chemical compound CC(C)(C)SCC1(CCC1)N RYKHPGZFNMXWDW-UHFFFAOYSA-N 0.000 description 1
- IDKAJTIEEAKXAB-VIFPVBQESA-N CC(C)(C[C@H]1C(C)=O)CN1C(C)=O Chemical compound CC(C)(C[C@H]1C(C)=O)CN1C(C)=O IDKAJTIEEAKXAB-VIFPVBQESA-N 0.000 description 1
- BZPQPVPJHFNVBZ-UHFFFAOYSA-N CC(C)C(C(CCC1)S1(=O)=O)N Chemical compound CC(C)C(C(CCC1)S1(=O)=O)N BZPQPVPJHFNVBZ-UHFFFAOYSA-N 0.000 description 1
- UPICKTKBODXMLV-QQGUTBHFSA-N CC(C)C(CC1)[C@@H](C(NC(CC2CC2)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)N)=O Chemical compound CC(C)C(CC1)[C@@H](C(NC(CC2CC2)C(C(NCC=C)=O)=O)=O)N1C([C@H](C(C)(C)C)N)=O UPICKTKBODXMLV-QQGUTBHFSA-N 0.000 description 1
- GXYQJIXEIRIDLP-GKAPJAKFSA-N CC([C@H](CC(C1)C#N)N1C(C)=O)=N Chemical compound CC([C@H](CC(C1)C#N)N1C(C)=O)=N GXYQJIXEIRIDLP-GKAPJAKFSA-N 0.000 description 1
- VBZMYSMYHXKMKD-ZFWWWQNUSA-N CC([C@H](C[C@@H](CNC(c1ccccc1)=O)C1)N1C(C)=O)=O Chemical compound CC([C@H](C[C@@H](CNC(c1ccccc1)=O)C1)N1C(C)=O)=O VBZMYSMYHXKMKD-ZFWWWQNUSA-N 0.000 description 1
- LCLGZJOOZDPYMD-XHNCKOQMSA-N CC([C@H]([C@@H](C1)[C@H](C2)C1(F)F)N2C(C)=O)=O Chemical compound CC([C@H]([C@@H](C1)[C@H](C2)C1(F)F)N2C(C)=O)=O LCLGZJOOZDPYMD-XHNCKOQMSA-N 0.000 description 1
- YNEOMWVPGBUDSS-BIIVOSGPSA-N CC([C@H]([C@H]([C@@H]1C2)C1(Br)Br)N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(Br)Br)N2C(C)=O)=O YNEOMWVPGBUDSS-BIIVOSGPSA-N 0.000 description 1
- XVFRTCCLVJBLIS-ZTTFNVLMSA-N CC([C@H]([C@H]([C@@H]1C2)C1(C1[IH]C1)[IH+])N2C(C)=O)=O Chemical compound CC([C@H]([C@H]([C@@H]1C2)C1(C1[IH]C1)[IH+])N2C(C)=O)=O XVFRTCCLVJBLIS-ZTTFNVLMSA-N 0.000 description 1
- BYTKZHNMDOUJEX-DTIOYNMSSA-N CCC([C@H](CC(CNC(C)=O)C1)N1C(C)=O)=O Chemical compound CCC([C@H](CC(CNC(C)=O)C1)N1C(C)=O)=O BYTKZHNMDOUJEX-DTIOYNMSSA-N 0.000 description 1
- AJBBFQOELYHZKI-SFYZADRCSA-N CCC([C@H](C[C@H](C1)Cl)N1C(C)=O)=O Chemical compound CCC([C@H](C[C@H](C1)Cl)N1C(C)=O)=O AJBBFQOELYHZKI-SFYZADRCSA-N 0.000 description 1
- QDIGXZLAMPUSFN-QWHCGFSZSA-N CCC([C@H]([C@@H](C(C)C)C(C1)=C)N1C(C)=O)=O Chemical compound CCC([C@H]([C@@H](C(C)C)C(C1)=C)N1C(C)=O)=O QDIGXZLAMPUSFN-QWHCGFSZSA-N 0.000 description 1
- QYGXLIWJFWERPR-OCCSQVGLSA-N CCC([C@H]([C@H](CC1)C2CCCC2)N1C(C)=O)=O Chemical compound CCC([C@H]([C@H](CC1)C2CCCC2)N1C(C)=O)=O QYGXLIWJFWERPR-OCCSQVGLSA-N 0.000 description 1
- MXMJVZCOFLQJQT-IZOREMLJSA-N CCC1(CCCCC1)NC(N[C@@H](C(C)(C)C)C(N(CCC1)[C@@H]1C(NC(CC1CC1)C(C(N)=O)=O)=O)=O)=O Chemical compound CCC1(CCCCC1)NC(N[C@@H](C(C)(C)C)C(N(CCC1)[C@@H]1C(NC(CC1CC1)C(C(N)=O)=O)=O)=O)=O MXMJVZCOFLQJQT-IZOREMLJSA-N 0.000 description 1
- KRQDJBAPRVIAFS-UHFFFAOYSA-N CCCCC(C(C(O)=O)O)NC(OC(C)(C)C)=O Chemical compound CCCCC(C(C(O)=O)O)NC(OC(C)(C)C)=O KRQDJBAPRVIAFS-UHFFFAOYSA-N 0.000 description 1
- BVALZCVRLDMXOQ-UHFFFAOYSA-N CCCCC[N+]([O-])=O Chemical compound CCCCC[N+]([O-])=O BVALZCVRLDMXOQ-UHFFFAOYSA-N 0.000 description 1
- KEZZCAIGKYUVRG-UHFFFAOYSA-N COC(C1(CCCCC1)C(CCCC1)S1(=O)=O)=O Chemical compound COC(C1(CCCCC1)C(CCCC1)S1(=O)=O)=O KEZZCAIGKYUVRG-UHFFFAOYSA-N 0.000 description 1
- DTSXSYLEZZWBFC-UHFFFAOYSA-N CSCC1(CC=CCC1)N=C=O Chemical compound CSCC1(CC=CCC1)N=C=O DTSXSYLEZZWBFC-UHFFFAOYSA-N 0.000 description 1
- BIKGIZXOBREFAD-RCOVLWMOSA-N C[C@@H](CC1)[C@@H](C(C)=O)N1C(C)=O Chemical compound C[C@@H](CC1)[C@@H](C(C)=O)N1C(C)=O BIKGIZXOBREFAD-RCOVLWMOSA-N 0.000 description 1
- ZWDCLCKNBAZGBO-RCOVLWMOSA-N C[C@@H](CC[C@H]1C(C)=O)N1C(C)=O Chemical compound C[C@@H](CC[C@H]1C(C)=O)N1C(C)=O ZWDCLCKNBAZGBO-RCOVLWMOSA-N 0.000 description 1
- GBNWJNFEDAXHSI-LWRMFSKNSA-N C[C@H](C1(C)C)C1(C(N(CCC1)C1(C1)C1=O)=O)NC(NC1(CS(c2ccccc2)(=O)=O)CCCCC1)=O Chemical compound C[C@H](C1(C)C)C1(C(N(CCC1)C1(C1)C1=O)=O)NC(NC1(CS(c2ccccc2)(=O)=O)CCCCC1)=O GBNWJNFEDAXHSI-LWRMFSKNSA-N 0.000 description 1
- XIUIHZJEWXCPKL-PJXYFTJBSA-N C[C@H](CCC[C@@H]1C)[C@]1(CSC(C)(C)C)N Chemical compound C[C@H](CCC[C@@H]1C)[C@]1(CSC(C)(C)C)N XIUIHZJEWXCPKL-PJXYFTJBSA-N 0.000 description 1
- GVGPTSVGGIWEPV-UHFFFAOYSA-N C[O]1c(ccc(OC(CCCC2)C2O)c2)c2OC1 Chemical compound C[O]1c(ccc(OC(CCCC2)C2O)c2)c2OC1 GVGPTSVGGIWEPV-UHFFFAOYSA-N 0.000 description 1
- MCFRTSHBKQNPED-UHFFFAOYSA-N NC(CC1CCC1)C(C(N)=O)=O Chemical compound NC(CC1CCC1)C(C(N)=O)=O MCFRTSHBKQNPED-UHFFFAOYSA-N 0.000 description 1
- OIVLGBZAVBVYAW-UHFFFAOYSA-N O=C=NC1(CCCCC1)C(CCCC1)S1(=O)=O Chemical compound O=C=NC1(CCCCC1)C(CCCC1)S1(=O)=O OIVLGBZAVBVYAW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54867004P | 2004-02-27 | 2004-02-27 | |
| US60/548670 | 2004-02-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800128593A Division CN101076516A (zh) | 2004-02-27 | 2005-02-24 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103102389A true CN103102389A (zh) | 2013-05-15 |
Family
ID=34961556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800128593A Pending CN101076516A (zh) | 2004-02-27 | 2005-02-24 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
| CN2012103533032A Pending CN103102389A (zh) | 2004-02-27 | 2005-02-24 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2005800128593A Pending CN101076516A (zh) | 2004-02-27 | 2005-02-24 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8067379B2 (enExample) |
| EP (1) | EP1730110B9 (enExample) |
| JP (1) | JP4714732B2 (enExample) |
| KR (2) | KR20130018418A (enExample) |
| CN (2) | CN101076516A (enExample) |
| AR (1) | AR048241A1 (enExample) |
| AT (1) | ATE470660T1 (enExample) |
| AU (1) | AU2005222060A1 (enExample) |
| BR (1) | BRPI0508085A (enExample) |
| CA (1) | CA2557495C (enExample) |
| CY (1) | CY1111212T1 (enExample) |
| DE (1) | DE602005021760D1 (enExample) |
| DK (1) | DK1730110T3 (enExample) |
| EC (1) | ECSP066791A (enExample) |
| ES (1) | ES2346233T3 (enExample) |
| HR (1) | HRP20100416T1 (enExample) |
| IL (1) | IL177544A (enExample) |
| MY (1) | MY145081A (enExample) |
| NO (1) | NO20064358L (enExample) |
| NZ (1) | NZ549223A (enExample) |
| PE (1) | PE20051150A1 (enExample) |
| PL (1) | PL1730110T3 (enExample) |
| PT (1) | PT1730110E (enExample) |
| RS (1) | RS51394B (enExample) |
| RU (1) | RU2428428C9 (enExample) |
| SG (1) | SG186041A1 (enExample) |
| SI (1) | SI1730110T1 (enExample) |
| TW (2) | TWI393704B (enExample) |
| WO (1) | WO2005087731A1 (enExample) |
| ZA (1) | ZA200607096B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024153137A1 (zh) * | 2023-01-17 | 2024-07-25 | 西藏海思科制药有限公司 | 一种手性氨基醇医药中间体的制备方法 |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69709671T2 (de) | 1996-10-18 | 2002-08-22 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus |
| NZ549223A (en) | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
| WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
| AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
| WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
| US20060276407A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
| WO2006130666A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
| US20070237818A1 (en) * | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
| US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
| CA2611145A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
| US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US20090220457A1 (en) * | 2006-03-03 | 2009-09-03 | Lahser Frederick C | Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto |
| US20070244334A1 (en) | 2006-03-16 | 2007-10-18 | Tanoury Gerald J | Processes and intermediates for preparing steric compounds |
| JP2009530382A (ja) * | 2006-03-23 | 2009-08-27 | シェーリング コーポレイション | Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法 |
| EP2007789B1 (en) | 2006-04-11 | 2015-05-20 | Novartis AG | Spirocyclic HCV/HIV inhibitors and their uses |
| DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
| WO2008019477A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2428204A3 (en) * | 2006-12-07 | 2012-07-04 | Schering Corporation | pH sensitive matrix formulation |
| EP2081922B1 (en) | 2006-12-22 | 2012-02-01 | Schering Corporation | 5,6-Ring annulated indole derivatives and use thereof |
| AU2007339386B8 (en) | 2006-12-22 | 2013-12-05 | Merck Sharp & Dohme Corp. | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
| JP5153648B2 (ja) * | 2006-12-22 | 2013-02-27 | 住友精化株式会社 | ３−ベンジルオキシベンゼンチオールの製造方法 |
| EP2064180B1 (en) | 2006-12-22 | 2016-07-13 | Merck Sharp & Dohme Corp. | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| CA2697375A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| KR20100065167A (ko) | 2007-08-29 | 2010-06-15 | 쉐링 코포레이션 | 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체 |
| KR20100067652A (ko) | 2007-08-29 | 2010-06-21 | 쉐링 코포레이션 | 치환된 인돌 유도체 및 이의 사용방법 |
| SI2061513T1 (sl) * | 2007-09-14 | 2011-11-30 | Schering Corp | Postopek zdravljenja pacientov s hepatitisom c |
| AU2008309589B2 (en) * | 2007-10-10 | 2012-07-05 | Novartis Ag | Spiropyrrolidines and their use against HCV and HIV infection |
| CN102099351A (zh) | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
| WO2009064852A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| AU2008338273B2 (en) | 2007-12-19 | 2014-10-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7964560B2 (en) * | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8901139B2 (en) | 2008-06-13 | 2014-12-02 | Merck Sharp & Dohme Corp. | Tricyclic indole derivatives and methods of use thereof |
| US20110207660A1 (en) * | 2008-08-07 | 2011-08-25 | Schering Corporation | Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion |
| US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| CA2746258A1 (en) | 2008-12-12 | 2010-06-17 | Schering Corporation | Deuterated compounds as hepatitis c virus (hcv) inhibitors |
| CA2750227A1 (en) | 2009-01-07 | 2010-07-15 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
| US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
| CA2763140A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
| GEP20207101B (en) | 2009-07-29 | 2020-05-11 | Merck Sharp & Dohme | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
| CN102918049A (zh) | 2010-03-09 | 2013-02-06 | 默沙东公司 | 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法 |
| AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| JP2013542929A (ja) | 2010-09-28 | 2013-11-28 | パナセア バイオテック リミテッド | 新規ビシクロ環化合物 |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| WO2012073249A1 (en) | 2010-12-01 | 2012-06-07 | Arch Pharmalabs Limited | A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs. |
| PH12013502141A1 (en) | 2011-04-13 | 2014-01-06 | Merck Sharp & Dohme | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| EP3063140A4 (en) | 2013-10-30 | 2017-11-08 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| US20180273573A1 (en) * | 2015-10-01 | 2018-09-27 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| US10874686B2 (en) | 2015-10-01 | 2020-12-29 | Memorial Sloan-Kettering Cancer Center | Anthranilyl-adenosinemonosulfamate analogs and uses thereof |
| JP7076438B2 (ja) * | 2016-06-21 | 2022-05-27 | オリオン・オフサルモロジー・エルエルシー | 脂肪族プロリンアミド誘導体 |
| EP3897667A4 (en) | 2018-12-21 | 2023-04-19 | Memorial Sloan Kettering Cancer Center | SALICYL-ADENOSINE MONOSULFAMATE ANALOGS AND THEIR USES |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062265A2 (en) * | 2002-01-18 | 2003-07-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2079105C (en) | 1990-04-04 | 2000-06-13 | Michael Houghton | Hepatitis c virus protease |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| DE69709671T2 (de) | 1996-10-18 | 2002-08-22 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| DE69827956T2 (de) | 1997-08-11 | 2005-04-14 | Boehringer Ingelheim (Canada) Ltd., Laval | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| JP4806154B2 (ja) | 2000-04-03 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター |
| MXPA02009920A (es) | 2000-04-05 | 2003-03-27 | Schering Corp | Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c9 que comprenden partes p2 n-ciclicas. |
| HUP0302957A2 (hu) | 2000-04-19 | 2003-12-29 | Schering Corporation | Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| ES2341534T3 (es) * | 2000-07-21 | 2010-06-22 | Schering Corporation | Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| AU8063701A (en) | 2000-07-21 | 2002-02-05 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| CA2418199A1 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| DE60138567D1 (de) | 2000-12-12 | 2009-06-10 | Schering Corp | Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus |
| US7241796B2 (en) * | 2001-10-24 | 2007-07-10 | Vertex Pharmaceuticals Inc. | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| NZ549223A (en) | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| AU2006252553B2 (en) | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
-
2005
- 2005-02-24 NZ NZ549223A patent/NZ549223A/en not_active IP Right Cessation
- 2005-02-24 PT PT05723607T patent/PT1730110E/pt unknown
- 2005-02-24 US US11/064,673 patent/US8067379B2/en active Active
- 2005-02-24 AU AU2005222060A patent/AU2005222060A1/en not_active Abandoned
- 2005-02-24 AT AT05723607T patent/ATE470660T1/de active
- 2005-02-24 CN CNA2005800128593A patent/CN101076516A/zh active Pending
- 2005-02-24 KR KR1020127034290A patent/KR20130018418A/ko not_active Withdrawn
- 2005-02-24 RS RSP-2010/0360A patent/RS51394B/sr unknown
- 2005-02-24 CN CN2012103533032A patent/CN103102389A/zh active Pending
- 2005-02-24 TW TW098107879A patent/TWI393704B/zh not_active IP Right Cessation
- 2005-02-24 AR ARP050100679A patent/AR048241A1/es not_active Application Discontinuation
- 2005-02-24 ES ES05723607T patent/ES2346233T3/es not_active Expired - Lifetime
- 2005-02-24 SI SI200531086T patent/SI1730110T1/sl unknown
- 2005-02-24 DE DE602005021760T patent/DE602005021760D1/de not_active Expired - Lifetime
- 2005-02-24 PL PL05723607T patent/PL1730110T3/pl unknown
- 2005-02-24 MY MYPI20050737A patent/MY145081A/en unknown
- 2005-02-24 PE PE2005000220A patent/PE20051150A1/es not_active Application Discontinuation
- 2005-02-24 CA CA2557495A patent/CA2557495C/en not_active Expired - Fee Related
- 2005-02-24 SG SG2012087664A patent/SG186041A1/en unknown
- 2005-02-24 WO PCT/US2005/005795 patent/WO2005087731A1/en not_active Ceased
- 2005-02-24 HR HR20100416T patent/HRP20100416T1/hr unknown
- 2005-02-24 TW TW094105518A patent/TWI314927B/zh not_active IP Right Cessation
- 2005-02-24 JP JP2007500955A patent/JP4714732B2/ja not_active Expired - Fee Related
- 2005-02-24 RU RU2006134003/04A patent/RU2428428C9/ru active
- 2005-02-24 KR KR1020067017257A patent/KR101316137B1/ko not_active Expired - Fee Related
- 2005-02-24 DK DK05723607.7T patent/DK1730110T3/da active
- 2005-02-24 EP EP05723607A patent/EP1730110B9/en not_active Expired - Lifetime
- 2005-02-24 BR BRPI0508085-1A patent/BRPI0508085A/pt not_active IP Right Cessation
-
2006
- 2006-08-17 IL IL177544A patent/IL177544A/en not_active IP Right Cessation
- 2006-08-24 ZA ZA200607096A patent/ZA200607096B/xx unknown
- 2006-08-25 EC EC2006006791A patent/ECSP066791A/es unknown
- 2006-09-26 NO NO20064358A patent/NO20064358L/no not_active Application Discontinuation
-
2010
- 2010-09-01 CY CY20101100796T patent/CY1111212T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062265A2 (en) * | 2002-01-18 | 2003-07-31 | Schering Corporation | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024153137A1 (zh) * | 2023-01-17 | 2024-07-25 | 西藏海思科制药有限公司 | 一种手性氨基醇医药中间体的制备方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103102389A (zh) | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的硫化合物 | |
| TWI302835B (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| EP1939213B1 (en) | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| US7718691B2 (en) | Compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| JP4745327B2 (ja) | Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター | |
| US20060046956A1 (en) | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease | |
| JP2008502718A (ja) | Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての置換型プロリン | |
| CN101679240A (zh) | Hcv ns3蛋白酶的p1-非可差向异构化酮酰胺抑制剂 | |
| HK1095819B (en) | Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1118066B (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| HK1095837B (en) | Novel compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| MXPA06009814A (en) | Inhibitors of hepatitis c virus ns3 protease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130515 |